Skip to main content
Thorax logoLink to Thorax
. 1993 Feb;48(2):148–153. doi: 10.1136/thx.48.2.148

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.

B Lundback 1, D W Rawlinson 1, J B Palmer 1
PMCID: PMC464292  PMID: 8493629

Abstract

BACKGROUND: Salmeterol is a potent selective beta 2 agonist that has been shown to have a duration of action in excess of 12 hours. In this study salmeterol and salbutamol were compared over a three month period with a further extension of nine months. METHODS: Three hundred and eighty eight patients with mild to moderate reversible airways obstruction (forced expiratory volume in one second (FEV1) > 50% predicted) were randomised to receive salmeterol (50 micrograms) twice daily or salbutamol (400 micrograms) four times daily, both by dry powder, in a double blind parallel group study. During the first three months detailed assessment of efficacy was made with recording of morning and evening peak expiratory flow rates (PEF), asthma symptoms, and bronchodilator use when necessary for the relief of symptoms. Patients continued in the study for a further nine months with the salbutamol dose reduced to 400 micrograms twice daily. Lung function was measured at the clinic and safety data were collected during this period. RESULTS: Salmeterol produced a significantly higher mean morning PEF (mean difference compared with salbutamol 21 (95% CI 12-31) l/min), and a significant reduction in mean diurnal variation in PEF (from 30 l/min at baseline to 11 34 l/min at baseline to 32 l/min during salbutamol treatment). Salmeterol also reduced day and night symptoms and use of rescue bronchodilator. FEV1 increased with both salmeterol and salbutamol treatment over the 12 month treatment period. For both treatments the number of patients reporting exacerbations of asthma and the frequency of these exacerbations remained constant during the study. Thirty six patients in the salmeterol and 49 in the salbutamol group withdrew during the 12 months of the study. CONCLUSIONS: In this study salmeterol (50 micrograms twice daily) was more effective than salbutamol (400 micrograms four times daily) in the control of asthma over three months, and more effective than salbutamol (400 micrograms twice daily) over a further nine months. Neither salmeterol nor salbutamol was associated with any worsening of control of asthma.

Full text

PDF
148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S. D., Rodwell L. T., Du Toit J., Young I. H. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest. 1991 Nov;100(5):1254–1260. doi: 10.1378/chest.100.5.1254. [DOI] [PubMed] [Google Scholar]
  2. Ball D. I., Brittain R. T., Coleman R. A., Denyer L. H., Jack D., Johnson M., Lunts L. H., Nials A. T., Sheldrick K. E., Skidmore I. F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991 Nov;104(3):665–671. doi: 10.1111/j.1476-5381.1991.tb12486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clark T. J. Choice of drug treatment in asthma. Pharmacol Ther. 1982;17(2):221–228. doi: 10.1016/0163-7258(82)90013-4. [DOI] [PubMed] [Google Scholar]
  4. Dahl R., Earnshaw J. S., Palmer J. B. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J. 1991 Nov;4(10):1178–1184. [PubMed] [Google Scholar]
  5. Gongora H. C., Wisniewski A. F., Tattersfield A. E. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):626–629. doi: 10.1164/ajrccm/144.3_Pt_1.626. [DOI] [PubMed] [Google Scholar]
  6. Larsson S., Svedmyr N. Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. Am Rev Respir Dis. 1977 Nov;116(5):861–869. doi: 10.1164/arrd.1977.116.5.861. [DOI] [PubMed] [Google Scholar]
  7. Malo J. L., Ghezzo H., Trudeau C., L'Archevêque J., Cartier A. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol. 1992 Feb;89(2):567–574. doi: 10.1016/0091-6749(92)90324-u. [DOI] [PubMed] [Google Scholar]
  8. McFadden E. R., Jr Aerosolized bronchodilators and steroids in the treatment of airway obstruction in adults. Am Rev Respir Dis. 1980 Nov;122(5 Pt 2):89–96. doi: 10.1164/arrd.1980.122.5P2.89. [DOI] [PubMed] [Google Scholar]
  9. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  10. Svedmyr N. Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1985 May-Jun;5(3):109–126. doi: 10.1002/j.1875-9114.1985.tb03409.x. [DOI] [PubMed] [Google Scholar]
  11. Tattersfield A. E. Bronchodilator drugs. Pharmacol Ther. 1982;17(3):299–313. doi: 10.1016/0163-7258(82)90019-5. [DOI] [PubMed] [Google Scholar]
  12. Taylor I. K., O'Shaughnessy K. M., Choudry N. B., Adachi M., Palmer J. B., Fuller R. W. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J Allergy Clin Immunol. 1992 Feb;89(2):575–583. doi: 10.1016/0091-6749(92)90325-v. [DOI] [PubMed] [Google Scholar]
  13. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES